These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35293329)

  • 1. Tumor Necrosis Factor-α Inhibition Before and After Rituximab Treatment in Juvenile Idiopathic Arthritis: What Shall We Expect? A Pilot Study.
    Marino A; Orsini F; Pregnolato F; Cimaz R
    J Rheumatol; 2022 Jun; 49(6):654-656. PubMed ID: 35293329
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab use in young adults diagnosed with juvenile idiopathic arthritis unresponsive to conventional treatment: report of 6 cases.
    Sakamoto AP; Pinheiro MM; Barbosa CM; Fraga MM; Len CA; Terreri MT
    Rev Bras Reumatol; 2015; 55(6):536-41. PubMed ID: 26066294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Tumor Necrosis Factor α Blockers on Growth Velocity in Juvenile Idiopathic Arthritis.
    Mrážik P; Vargová V; Košková E
    J Clin Rheumatol; 2015 Oct; 21(7):376-8. PubMed ID: 26398470
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel therapies for the treatment of juvenile rheumatoid arthritis (juvenile idiopathic arthritis).
    Agle LM; Rosenkranz M; Lehman TJ
    Expert Opin Investig Drugs; 2003 Jan; 12(1):19-28. PubMed ID: 12517251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiologic Improvement of juvenile idiopathic arthritis-enthesitis-related arthritis following anti-tumor necrosis factor-alpha blockade with etanercept.
    Tse SM; Laxer RM; Babyn PS; Doria AS
    J Rheumatol; 2006 Jun; 33(6):1186-8. PubMed ID: 16755667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insurance Delays in Initiation of Tumor Necrosis Factor Inhibitors in Children With Juvenile Idiopathic Arthritis.
    Roberts JE; Fan M; Son MBF
    JAMA Netw Open; 2022 Apr; 5(4):e228330. PubMed ID: 35446398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Sieper J; Emery P; Keystone EC; Schiff MH; Mease P; van Riel PL; Fleischmann R; Weisman MH; Weinblatt ME
    Ann Rheum Dis; 2007 Nov; 66 Suppl 3(Suppl 3):iii2-22. PubMed ID: 17934088
    [No Abstract]   [Full Text] [Related]  

  • 8. Rapid Resolution of Erosive Psoriatic Juvenile Idiopathic Arthritis With Anti-Tumor Necrosis Factor Therapy.
    Felix MD; Ostrov BE
    J Clin Rheumatol; 2021 Dec; 27(8S):S688-S689. PubMed ID: 33136694
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of juvenile idiopathic arthritis in the biologic age.
    Stoll ML; Cron RQ
    Rheum Dis Clin North Am; 2013 Nov; 39(4):751-66. PubMed ID: 24182853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic Variants and Therapeutic Response to Anti-TNF-α Agents in Juvenile Idiopathic Arthritis: An Updated Systematic Review and Meta-analysis.
    Pregnolato F; Chighizola CB; Giani T; Costi S; Marino A; Cimaz R
    J Clin Rheumatol; 2022 Oct; 28(7):374-378. PubMed ID: 35777854
    [No Abstract]   [Full Text] [Related]  

  • 11. [Biological therapy treatment of juvenile idiopathic arthritis].
    Herlin T
    Ugeskr Laeger; 2008 Jun; 170(24):2105-8. PubMed ID: 18565289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis.
    Lee WJ; Briars L; Lee TA; Calip GS; Suda KJ; Schumock GT
    Pharmacotherapy; 2016 Dec; 36(12):1201-1209. PubMed ID: 27779782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the treatment of juvenile idiopathic arthritis.
    Harris JG; Kessler EA; Verbsky JW
    Curr Allergy Asthma Rep; 2013 Aug; 13(4):337-46. PubMed ID: 23605168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor inhibitors and cancer in juvenile idiopathic arthritis: disentangling the web.
    Onel KB; Onel K
    Arthritis Rheum; 2012 Apr; 64(4):966-9. PubMed ID: 22327954
    [No Abstract]   [Full Text] [Related]  

  • 15. Response to etanercept in juvenile idiopathic arthritis.
    Pang H; Wu XH; Xu JZ
    JAMA; 2012 Mar; 307(11):1140; author reply 1140-1. PubMed ID: 22436950
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical trials for the treatment of systemic onset juvenile rheumatoid arthritis-juvenile idiopathic arthritis.
    Lehman TJ
    Curr Rheumatol Rep; 2000 Aug; 2(4):313-5. PubMed ID: 11123076
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-tumor necrosis factor therapy is tolerated in an individual with homozygous complement C2 deficiency.
    Momeni M; Mehta AP; Katz JD
    J Clin Rheumatol; 2005 Jun; 11(3):180-2. PubMed ID: 16357744
    [No Abstract]   [Full Text] [Related]  

  • 18. Herpes Virus Infections During Treatment With Etanercept in Juvenile Idiopathic Arthritis.
    Nicolai R; Cortis E; Ravà L; Bracaglia C; Pardeo M; Insalaco A; Buonuomo PS; Tozzi AE; De Benedetti F
    J Pediatric Infect Dis Soc; 2016 Mar; 5(1):76-9. PubMed ID: 26908493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Juvenile idiopathic arthritis: current and future treatment options.
    Martini G; Zulian F
    Expert Opin Pharmacother; 2006 Mar; 7(4):387-99. PubMed ID: 16503811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.
    Ruperto N; Lovell DJ; Quartier P; Paz E; Rubio-Pérez N; Silva CA; Abud-Mendoza C; Burgos-Vargas R; Gerloni V; Melo-Gomes JA; Saad-Magalhães C; Sztajnbok F; Goldenstein-Schainberg C; Scheinberg M; Penades IC; Fischbach M; Orozco J; Hashkes PJ; Hom C; Jung L; Lepore L; Oliveira S; Wallace CA; Sigal LH; Block AJ; Covucci A; Martini A; Giannini EH; ;
    Lancet; 2008 Aug; 372(9636):383-91. PubMed ID: 18632147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.